Moneycontrol PRO
Jump to
  • Sun Pharma's Halol unit: Observations are minor & could be remedied easily, says Nirmal Bang Mar 06, 2018 10:10 AM IST

    Sun Pharma's Halol unit: Observations are minor & could be remedied easily, says Nirmal Bang

    In an interview with CNBC-TV18, Vishal Manchanda of Nirmal Bang Institutional Equities spoke about the observations and gave his views on the stock.

  • Industry facing pricing & competition problems: Sun Pharma Feb 16, 2018 02:19 PM IST

    Industry facing pricing & competition problems: Sun Pharma

    The EY Entrepreneur of The Year Awards was held in Mumbai. From the sidelines, Priya Sheth caught up with Dilip Shanghvi of Sun Pharmaceutical Industries and began by asking his outlook on pharma industry amid rising pricing pressure.

  • Will continue to pursue inorganic growth in India & US: Torrent Pharma Nov 07, 2017 12:19 PM IST

    Will continue to pursue inorganic growth in India & US: Torrent Pharma

    In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

  • Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols Oct 13, 2017 04:34 PM IST

    Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols

    In an interview to CNBC-TV18, Rajesh Agrawal, CFO of Gulshan Polyols spoke about the latest happenings in the company and his outlook going ahead.

  • Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality Aug 17, 2017 01:10 PM IST

    Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality

    In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.

  • Sun Pharma survives tax evasion charge on IPR transfer to foreign arm Jul 27, 2017 03:37 PM IST

    Sun Pharma survives tax evasion charge on IPR transfer to foreign arm

    CNBC-TV18 learns that Sun Pharma survives 'tax evasion' charge on intellectual property rights (IPR) transfer to foreign arm.

  • No scope of US intervention in Indian pharma cos: Wockhardt Jan 12, 2017 01:07 PM IST

    No scope of US intervention in Indian pharma cos: Wockhardt

    Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

  • GST positive step for Indian industry, consumers: Dilip Shanghvi Oct 24, 2016 09:00 AM IST

    GST positive step for Indian industry, consumers: Dilip Shanghvi

    The goods and services tax (GST) bill is an extremely positive step for both the Indian industry and consumer as it will facilitate the long term economic growth in the country, says Dilip Sanghvi, CMD of Sun Pharma.

  • ITI Reinsurance may kick off ops in October this year: Sources Jul 20, 2016 03:44 PM IST

    ITI Reinsurance may kick off ops in October this year: Sources

    ITI Reinsurance, a subsidiary of Fortune Financial Services, may get IRDA nod by September. It will start with Rs 500 crore initial cap, learns CNBC-TV18.

  • Rollout of InfuSMART to begin with UK, Netherlands: Sun Pharma Jul 11, 2016 01:24 PM IST

    Rollout of InfuSMART to begin with UK, Netherlands: Sun Pharma

    Hellen De Kloet, Biz Head-Western Europe & ANZ, Sun Pharma said the launch of ‘Gemcitabine InfuSMART‘ will start in the UK and the Netherlands because these are the first two countries in Europe where we have final approval.

  • Regulatory risks waning in pharma sector: IIFL Jul 11, 2016 09:04 AM IST

    Regulatory risks waning in pharma sector: IIFL

    “Regulatory risks are waning in the sector,” says Abhishek Sharma, pharma analyst at IIFL. Hereon, things are expected to move in positive direction for companies.

  • Lupin to see approvals after US FDA gives clean chit: Macquarie Jul 08, 2016 09:11 AM IST

    Lupin to see approvals after US FDA gives clean chit: Macquarie

    Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.

  • Sun's psoriasis trial drug won't hit mkt before FY19: Analyst May 05, 2016 10:33 AM IST

    Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

    Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

  • Sun Pharma inks pact with ICGEB for dengue drug Cipa May 04, 2016 01:42 PM IST

    Sun Pharma inks pact with ICGEB for dengue drug Cipa

    Cipa will help in treating about 7.5-34 million people, the number of cases reported for dengue, says Kirti Ganorkar, Senior VP - Business Development & Portfolio Management at Sun Pharma.

  • Sun Pharma joins hands with ICMR for malaria eradication prog Apr 26, 2016 11:59 AM IST

    Sun Pharma joins hands with ICMR for malaria eradication prog

    The project will first be launched in malaria-ridden district of Mandla in Madhya Pradesh, says Altaf Lal, Senior Advisor, Global Health & Innovation at Sun Pharma.

  • Indian pharma cos need to step-up safeguards at plants: Handa Mar 29, 2016 09:29 PM IST

    Indian pharma cos need to step-up safeguards at plants: Handa

    In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

  • Pharma cos facing pricing pressure in US: PhillipCap Nov 09, 2015 12:36 PM IST

    Pharma cos facing pricing pressure in US: PhillipCap

    In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.

  • Elepsia drug more relevant to Sun Pharma: Phillipcap Sep 28, 2015 11:19 AM IST

    Elepsia drug more relevant to Sun Pharma: Phillipcap

    Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues

  • Integration costs to continue into FY16: Sun Pharma Jun 01, 2015 01:19 PM IST

    Integration costs to continue into FY16: Sun Pharma

    Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

  • Strides Arcolab to buy Aspen's generic biz in Australia May 21, 2015 01:02 PM IST

    Strides Arcolab to buy Aspen's generic biz in Australia

    The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.

  • No plan to merge SPARC with Sun Pharma: Dilip Shanghvi Mar 25, 2015 07:18 PM IST

    No plan to merge SPARC with Sun Pharma: Dilip Shanghvi

    With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion

  • Sun Pharma to buy GSK's opiates business in Australia Mar 03, 2015 09:00 AM IST

    Sun Pharma to buy GSK's opiates business in Australia

    The transaction is expected to close by August 2015.

  • Sun Pharma maintains 13-15% FY15 topline guidance: CFO Feb 18, 2015 02:54 PM IST

    Sun Pharma maintains 13-15% FY15 topline guidance: CFO

    The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.

  • Mineral-based projects will get sorted in 2 yrs: JSW Steel Feb 12, 2015 10:17 PM IST

    Mineral-based projects will get sorted in 2 yrs: JSW Steel

    Sajjan Jindal, Chairman & MD, JSW Steel says with iron-ore and mining ordinances, it has become very clear that now it will be through the auction route, through a transparent route. So, I think over the next two years, all these large projects which are mineral based will get sorted out.

  • Sun's margins may reduce to 30-32% post merger: Surajit Pal Dec 29, 2014 12:36 PM IST

    Sun's margins may reduce to 30-32% post merger: Surajit Pal

    As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.